Hugo Mouquet

Sorry, this entry is only available in FR.

Chikungunya is a mosquito-transmitted disease of sub-tropical areas caused by an alphavirus, the Chikungunya virus (CHIKV). CHIKV infection has re-emerged after several decades causing large outbreaks, making it an important public health concern. The […]

Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers HIV-1 post-treatment controllers (PTC) are rare individuals controlling HIV-1 infection for years after antiretroviral therapy interruption. Identification of immune correlates of control […]

HBV infection can be successfully controlled by natural immune responses in more than 90% of the patients infected as adults, and in the ~1% of chronically infected patients who spontaneously clear the infection (also […]

HIV-1 potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against omicron BA.1 and BA.2 Memory B-cell and antibody responses to the SARS-CoV-2 spike protein contribute to long-term immune protection against severe COVID-19, […]

This page contains the list of past meetings held by the Group for AIDS Research (Groupe de Réflexion SIDA) of the Pasteur Institute since 2014. The list of previous meetings held since 2002 can […]

The Group for AIDS Research (Groupe de Réflexion SIDA, GRS) organizes meetings and seminars around an HIV / AIDS research topic. Since 2021, the meetings may also include topics related to emerging viruses. Meetings […]

Mucosal transmission of HIV-1 can induce a local production of IgG and IgA antibodies predominantly targeting the gp41 subunit of the viral envelope glycoprotein gp160. However, whether they limit viral dissemination upon HIV-1 exposure […]

Hepatitis C virus (HCV) infection can trigger the development of an autoimmune disorder called cryobulininemic vasculatitis. HCV-associated cryobulininemic vasculatitis (HCV-CV) is mediated by mono-/oligo-clonal IgM cryoglobulins with rheumatoid factor activity, thought to be produced […]

Broadly neutralizing HIV-1 antibodies (bNAbs) can develop in rare infected individuals several years after co-evolution with diversifying viruses. In animal models, passive immunotherapy with potent HIV-1 bNAbs has been shown to protect from infection […]

Human Antibody Responses to Viruses Adaptive immune responses naturally occurring upon infection or induced by vaccination generate high affinity antibodies, and memory B-cell subsets to respond to further antigenic challenges, providing protection against (re-)infections. […]